1 Enteric viruses exploit bacterial components including lipopolysaccharides (LPS) and 2 peptidoglycan (PG) to facilitate infection in humans. With origins in the bat enteric system, we 3 wondered if severe acute respiratory syndrome-coronavirus (SARS-CoV) or Middle East 4 respiratory syndrome-CoV (MERS-CoV) also use bacterial components to modulate infectivity. 5 To test this question, we incubated CoVs with LPS and PG and evaluated infectivity finding no 6 change following LPS treatment. However, PG from B. subtilis reduced infection >10,000-fold 7
Abstract 1
Enteric viruses exploit bacterial components including lipopolysaccharides (LPS) and 2 peptidoglycan (PG) to facilitate infection in humans. With origins in the bat enteric system, we 3 wondered if severe acute respiratory syndrome-coronavirus (SARS-CoV) or Middle East 4 respiratory syndrome-CoV (MERS-CoV) also use bacterial components to modulate infectivity. 5
To test this question, we incubated CoVs with LPS and PG and evaluated infectivity finding no 6 change following LPS treatment. However, PG from B. subtilis reduced infection >10,000-fold 7 while PG from other bacterial species failed to recapitulate this. Treatment with an alcohol 8 solvent transferred inhibitory activity to the wash and mass spectrometry revealed surfactin, a 9 cyclic lipopeptide antibiotic, as the inhibitory compound. This antibiotic had robust dose-and 1 0 temperature-dependent inhibition of CoV infectivity. Mechanistic studies indicated that surfactin 1 1 disrupts CoV virion integrity and surfactin treatment of the virus inoculum ablated infection in 1 2 vivo. Finally, similar cyclic lipopeptides had no effect on CoV infectivity and the inhibitory effect 1 3 of surfactin extended broadly to enveloped viruses including influenza, Ebola, Zika, Nipah, 1 4
Chikungunya, Una, Mayaro, Dugbe, and Crimean-Congo hemorrhagic fever viruses. Overall, 1 5
our results indicate that peptidoglycan-associated surfactin has broad virucidal activity and 1 6 suggest bacteria byproducts may negatively modulate virus infection. 1 7 Importance 1
In this manuscript, we considered a role for bacteria in shaping coronavirus infection. Taking 2 cues from studies of enteric viruses, we initially investigated how bacterial surface components 3 might improve CoV infection. Instead, we found that peptidoglycan-associated surfactin is a 4 potent viricidal compound that disrupts virion integrity with broad activity against enveloped 5 viruses. Our results indicate that interactions with commensal bacterial may improve or disrupt 6 viral infections highlighting the importance of understanding these microbial interactions and 7 their implications for viral pathogenesis and treatment. 8 9 \Body 1 Introduction 2 Commensal bacteria inhabit nearly every surface of the human body, influencing numerous host 3 processes (1, 2). While considered to serve a protective role, recent studies indicate enteric 4 viruses exploit bacterial envelope components to facilitate infection (3). Poliovirus was found to 5 bind both lipopolysaccharides (LPS) and peptidoglycan (PG) to enhance its thermostability and 6 receptor affinity, facilitating in vivo infection (3). Antibiotic depletion of commensal bacteria 7 inhibited oral poliovirus infection, but was rescued by recolonization, pretreatment of virus with 8 LPS, or bypassing the enteric system through intraperitoneal injection (3). Other viruses 9 including reovirus, mouse mammary tumor virus, and murine norovirus have been shown to use 1 0 similar mechanisms to facilitate infection (3, 4) . Together, these results indicate a key role for 1 1 commensal bacteria in improving infectivity and pathogenesis of enteric viruses. 1 2 Like the enteric system, the respiratory tract harbors high levels of commensal bacteria (1). 1 3
Given the origins of Severe Acute Respiratory Syndrome-Coronavirus (SARS-CoV) and Middle 1 4
East Respiratory Syndrome (MERS)-CoV in the bat enteric system (5), we wondered if CoVs 1 5 utilized bacterial components to facilitate infection. Previous work had identified a key role for 1 6 the TLR pathways in immunity to SARS-CoV with the absence of LPS binding TLR4 or its 1 7 downstream adaptors resulting in augmented disease (6) (7) (8) . Given the interactions observed 1 8 between enteric viruses and bacterial components, CoVs may also use similar microbial 1 9 components to improve infectivity and subsequently stimulate the TLR4 response. 2 0
In this study, we explored the relationship between bacterial surface components and CoV 2 1 infection. Surprisingly, we found PG from Bacillus subtilis reduced CoV infectivity. Using mass 2 2 spectrometry, we identified a cyclic lipopeptide (CLP), surfactin, as the molecule responsible for 2 3
CoV inhibition. Surfactin's inhibitory effect was dose and temperature dependent with treatment 2 4 disrupting the integrity of the CoV particle. Notably, surfactin treatment of the inoculum ablated 1 CoV infection in vivo, but prophylactic treatment had no effect. Other similar CLPs had no effect 2 on CoV infectivity suggesting surfactin's virucidal properties were unique. Importantly, surfactin 3 treatment reduced the infectivity of several other enveloped viruses, including influenza A, Zika, 4
Dugbe, Nipah, Crimean-Congo Hemorrhagic Fever, chikungunya, Mayaro, Una, and Ebola 5 viruses. Together, these results demonstrate the efficacy of surfactin as a virucidal compound 6 and highlight the potential for microbial environment to modulate virus infection. 7 infectivity (Fig. 6A) . Despite similar biochemical structures, none of the CLPs tested had a 1 significant effect on HCoV-229 or MERS-CoV infection (Fig. 6B) . These results suggest that 2 unique features allow surfactin to reduce CoV infectivity. 3
Surfactin broadly reduces viral infectivity 4
With its potent antiviral properties against CoVs, we wanted to test surfactin's effect against 5 other highly pathogenic viruses. Given its ability to disrupt virion integrity, we focused on 6 enveloped viruses from diverse families including two Influenza A strains (H1N1, H3N2), Zika 7 Virus (ZIKV), Dugbe Virus (DUGV), Nipah Virus (NiV), Crimean-Congo Hemorrhagic Fever 8 Virus (CCHFV), Chikungunya Virus (CHIKV), Mayaro virus, Una virus, and Ebola virus (EBOV). 9
As a negative control, we tested the non-enveloped Coxsackievirus B3 (CVB3). Each virus was 1 0 treated with either PBS or surfactin and viral infectivity determined. As expected, surfactin had 1 1 no effect on the non-enveloped CVB3 (Fig. 6C) . In contrast, surfactin significantly reduced 1 2 infectivity in each of the enveloped viruses ( Fig. 6C) , but the magnitude of effect was not 1 3 uniform. Most enveloped viruses were reduced either below their limit of detection or greater 1 4 than 100,000-fold. In contrast, Mayaro, both influenza strains, and EBOV exhibited some 1 5 resistance, having their infectious titer reduced only 2.6, 2.7, 2.4, and 1.6 logs, respectively. 1 6
These data suggest that while surfactin treatment broadly reduced the infectivity of enveloped 1 7 viruses, factors beyond the mere presence or absence of an envelope may govern overall 1 8 sensitivity. 1 9
Discussion 1
In this study, we explored the relationship between bacterial components and CoV infection. 2 While initially predicting enhanced infection, treatment with B. subtilis PG reduced CoV 3 infectivity, while envelope components from other bacteria had no effect. Separating the 4 inhibitory effect using solvent washes, we used mass spectrometry to identify that the CLP 5 surfactin was responsible for reduced CoV infectivity and disruption of virion integrity. 6
Unfortunately, despite efficacy against the inoculum, prophylactic surfactin treatment prior to 7 infection had no effect on CoV related disease in vivo. Notably, other CLPs had no effect on 8
CoV infectivity despite having similar biochemical structures. Finally, we found that surfactin 9 treatment was efficacious against many enveloped viruses in vitro including IAV strains H1N1 1 0 and H3N2, ZIKV, DUGV, NiV, CCHFV, CHIKV, Una, Mayaro, and EBOV. Together, these data 1 1 demonstrate that surfactin is a potent virucide and highlight that interactions with bacterial 1 2 derived compounds can also negatively modulate virus infection. 1 3
Over the last two decades, surfactin has been shown to be anti-bacterial, anti-fungal, and anti-1 4 viral (11, 12, (17) (18) (19) . Mechanistically, surfactin's broad anti-microbial efficacy has been linked to 1 5 disruption of lipid membranes (13). However, more recently, researchers described surfactin's 1 6 efficacy against the animal CoV porcine epidemic diarrhea virus (PEDV), and suggested that 1 7 surfactin inhibited viral-host membrane fusion (19) . In contrast to the PEDV results, we found 1 8 that surfactin treatment disrupted virion integrity, exposing the viral RNA to RNase I mediated 1 9 degradation ( Fig. 4A-B ). Transmission electron microscopy (TEM) confirmed the absence of 2 0 intact virions in surfactin treated samples ( Fig. 4C) . Thus, while both PEDV and human CoVs 2 1 are sensitive to surfactin treatment, infectivity reduction may be the result of different 2 2 mechanisms due to differences the surfactin dose, virion composition, tissue environment 2 3 (respiratory vs enteric), or other factor.
4
Similar to the question of mechanism, in vivo efficacy of surfactin also varied between PEDV 1 and human CoVs. While surfactin ablates SARS-CoV disease when treating the inoculum, 2 prophylactic treatment was not protective. Why surfactin failed to protect mice against SARS-3
CoV is puzzling, given that efficacy of prophylactic oral surfactin treatment against PEDV 4 disease (19). One explanation is the physical environment of the respiratory and gastrointestinal 5 tracts differs significantly, making intranasal (IN) surfactin administration ineffective due to tissue 6 specific differences. Thus, while oral surfactin administration may be effective at delivering 7 surfactin to infected gastrointestinal tissue, IN administration may not be as effective, 8 particularly in the lower parts of the lung. Alternative delivery methods such as the inhalation of 9 an aerosolized surfactin may overcome these problems. Additionally, several surfactin 1 0 derivatives exist and may enhance its virucidal activity in the context of respiratory infection in 1 1 vivo (11, 12). 1 2
In addition to CoVs, we examined surfactin's virucidal efficacy against other enveloped viruses, 1 3 discovering broad efficacy, but wide variation. While all tested enveloped viruses were sensitive 1 4 to surfactin treatment, IAV strains H1N1 and H3N2, Mayaro, and EBOV demonstrated a degree 1 5 of resistance. These data suggest that factors beyond the mere presence of a viral envelope 1 6 regulate surfactin efficacy. One possible factor is the lipid content of the viral envelope. Previous 1 7 studies have shown that membranes enriched in cholesterol and phosphatidylethanolamines 1 8 (PE) are resistant to surfactin permeabilization, while membranes containing 1 9 phosphatidylcholines (PC) are more sensitive (20). The envelope of Influenza A viruses have 2 0 been reported to be enriched for both cholesterol and PE (21), providing support for this 2 1 hypothesis. Unfortunately, the lipid content of the other viruses tested have not been 2 2 determined, preventing direct comparison. Nevertheless, some broad observations are worth 2 3 mentioning. CoVs, ZIKV, and bunyaviruses (CCHFV and DUGV) derive their envelopes from 2 4 either the Golgi Apparatus and Endoplasmic Reticulum, organelles enriched in surfactin 2 5 sensitive PC (22) . NiV (23), IAV (24), EBOV (25) are thought to derive their envelopes from 1 lipid rafts of the plasma membrane , which could specify their lipid content and thus surfactin 2 sensitivity. Alphaviruses such as CHIKV, Mayaro, and Una also bud form the plasma 3 membrane, though neither the lipid content, nor the involvement of lipid rafts has been explored 4 (26). Together, these observations suggest the lipid content of enveloped viruses may explain 5 their differential sensitivity to surfactin. 6
The failure of other CLPs to reduce CoV infectivity is also surprising, given the structural 7 similarity to surfactin. In particular, Iturin A is both biochemically similar to surfactin and has 8 also been reported to disrupt lipid membranes ( Fig. 6A) (11) . A possible explanation involves 9 differences in their mechanisms of action. Surfactin penetrates lipid layers, alone solubilizing 1 0 and permeabilizing them (13). In contrast, Iturin A must interact with sterol components to cause 1 1 membrane permeabilization, explaining its broad anti-fungal, but only selective antibacterial 1 2 activity (11). However, Iturin A is also quite hemolytic (11, 12), making it unclear why the 1 3 membranes of enveloped viruses grown in mammalian cells would not also be susceptible to 1 4 this mechanism, due to the presence of sterols. Compounding this mechanistic uncertainty, 1 5 daptomycin's permeabilization of membranes requires no such interaction, but CoVs are 1 6 resistant to its effects as well (27) (Fig. 6B) . The results argue that surfactin possesses unique 1 7
properties conferring its virucidal activity. Surfactin is known to adopt a unique β -sheet like 1 8 "horse-saddle" conformation, which may facilitate membrane permeabilization (13). Molecular 1 9 dynamics simulations suggest temperature directly regulates the openness of the horse saddle 2 0 structure and may explain why surfactin's virucidal activity is also temperature sensitive (28). In 2 1 total, these results highlight our poor understanding of membrane disruption by CLPs and 2 2 argues that biochemical studies of these compounds inhibition of enveloped viruses are 2 3 needed.
While the microbiome has historically been thought to serve a protective role against pathogens 1 (1, 2), recent studies with viruses complicate this view. Studies with poliovirus demonstrated 2 that the presence of commensal bacteria is necessary for oral poliovirus infection in mice (29) . 3
Similar findings with other enteric viruses suggest that utilizing bacterial components is a 4 common approach. In contrast, our results add further complexity, demonstrating that surfactin, 5 a secondary metabolite of B. subtilis, can potently reduce CoV infectivity. Though B. subtilis is 6 not generally part of the human microbiome (30), it is often used as an intestinal probiotic and 7 has been found to transiently persist in the gut (31). Additionally, surfactin-like molecules are 8 produced by a broad array of bacterial species (11, (32) (33) (34) . For example, the novel surfactin like 9 CLP Coryxin was recently found to be produced by Corynebacterium xerosis, a common 1 0 member of the respiratory microbiome (34). These facts suggest that microbial components 1 1 typically thought to work against bacterial competitors could also potentially disrupt viral 1 2 infection. Thus, as the relationship between the microbiome and viral infections is further 1 3 explored, the role bacterial metabolites such as surfactin and other CLPs play in modulating 1 4 infection must be considered in viral disease. Overall, these results highlight the dynamic 1 5 microbial environment and its potential to impact viral pathogenesis as well as identify novel 1 6 inhibitory factors for therapeutic use. colisitn (C4461), ramoplanin (R1781), and daptomycin (D2446) were also purchased from 1 Sigma-Aldrich. 2 Mass spectrometry. Stock peptidoglycan was centrifuged at 15,000g for 1 minute in a table top 3 centrifuge and the insoluble PG fraction was then resuspended in 100% ethanol. Following a 5-4 minute incubation at room temperature, samples were centrifuged, and the supernatant and 5 insoluble fractions were used for treatment of viruses or delivered to the mass spectrometry 6 core facility. 1 µl of peptidoglycan was combined 1:1 with a 10 mg/ml α -cyano-4-7 hydroxycinnamic acid (60% acetonitrile) and spotted onto MALDI targets. All MALDI-MS 8 experiments were performed using a 5800 MALDI-TOF/TOF (Applied Biosystems). The MS 9 data were acquired using the reflectron detector in positive mode (700-4500 Da, 1900 Da focus 1 0 mass) using 300 laser shots (50 shots per sub-spectrum). Collision induced dissociation tandem 1 1 MS spectra were acquired using 1 kV of collision energy. Fragmentation data was analyzed 1 2 manually to determine structural information. were treated for 20 minutes with HCoV-229E samples. Excess sample solution was then wicked 1 7 off with filter paper, and each grid was then stained for 45 seconds with 2% Uranyl-acetate 1 8 solution. Excess stain was again wicked off with filter paper. Grids were then dried and 1 9 visualized on a Philips CM100 TEM Electron microscope. Images were recorded with a Gatan 2 0
Orius SC200 CCD camera. In order to ensure even counting, 10 pictures were taken on 3 2 1 different cells on each grid. No more than 10 minutes were allotted for looking for virus in each 2 2 cell.
3
RNase I protection assay. Assays were performed in accordance with standard protocols 2 4 described previously (47). Briefly, Samples were treated either with or without 250U RNase I for 2 5 1 from Zymo Research (R1034-1-100) with 2-mercaptoethanol was added. RNA was then 2 extracted using the Quick-RNA Viral Kit from Zymo Research (R1035). RNA was then 3 converted into cDNA using the iScript cDNA synthesis Kit (170-8891) from Bio-Rad. 4
Quantitative real time PCR was performed using SsoAdvanced Universal SYBR Green 5 Supermix (172-5271) from Bio-Rad. HCoV-229E specific primer sequences were Forward: 5-6 TGACATTCGCGACTACAAGC-3 and Reverse: 5-TAACGGTGGTTTGGCTTTTC-3. MERS-CoV 7 specific primer sequences were Forward: 5-TCGCTTGGCAAATGAGTGTG-3 and Reverse: 5-8 ACATTAGCAGTTGTCGCCTG-3. 9
Statistical analysis. All statistical comparisons in this manuscript involved the comparison 1 0 between 2 groups, untreated control virus and peptidoglycan/surfactin treated virus. Thus, 1 1 significant differences in viral titer, TEM counts, RNA levels, and weight loss were determined 1 2 by the unpaired two-tailed students T-Test. Mice and in vivo infection. Ten-week old BALB/c mice were purchased from Charles River 1 8
Laboratories and maintained in Sealsafe TM HEPA-filtered air in/out units. Animals were 1 9 anesthetized with isoflurane and infected intranasally (IN) with 10 4 PFU in 50 μ l of phosphate-2 0 buffered saline (PBS). Infected animals were monitored for weight loss, morbidity, and clinical 2 1 signs of disease, and lung titers were determined as described previously (48 . K  i  n  d  l  e  r  E  ,  J  ó  n  s  d  ó  t  t  i  r  H  R  ,  M  u  t  h  D  ,  H  a  m  m  i  n  g  O  J  ,  H  a  r  t  m  a  n  n  R  ,  R  o  d  r  i  g  u  e  z  R  ,  G  e  f  f  e  r  s  R  ,  F  o  u  c  h  i  e  r  R  A  ,  1  D  r  o  s  t  e  n  C  ,  M  ü  l  l  e  r  M  A  ,  D  i  j  k  m  a  n  R  ,  T  h  i  e  l  V  .  2  0  1  3  .  E  f  f  i  c  i  e  n  t  r  e  p  l  i  c  a  t  i  o  n  o  f  t  h  e  n  o  v  e  l  h  u  m  a  n  2  b  e  t  a  c  o  r  o  n  a  v  i  r  u  s  E  M  C  o  n  p  r  i  m  a  r  y  h  u  m  a  n  e  p  i  t  h  e  l  i  u  m  h  i  g  h  l  i  g  h  t  s  i  t  s  z  o  o  n  o  t  i  c  p  o  t  e  n  t  i  a  l  .  M  B  i  o  3  4  :  e  0  0  6  1  1  -1 MERS-CoV (n=5) after treatment with PBS alone (black), LPS from Escherichia coli (grey), or and viral infectivity determined (n=3). For dot plots, each point represents the titer from an 1 independent experiment while the group mean is indicated by a line. Each point on the line 2 graph represents the group mean. All error bars represent SD. The two tailed students t-test 3 was used to determine P-values: * P < 0.05, ** P < 0.01, *** P < 0.001. 4 Lung tissue was harvested and viral titer determined at day 2 and day 4. n=4 for all infected 1 7 groups, n=2 for mock groups. (C and D) BALB/C mice were pretreated intranasally with 50 μ l of 1 8 either PBS (black) or surfactin in PBS (red). 18 hours later, BALB/C mice were infected with 10 4 1 9 PFU of SARS-CoV (MA15) and (C) monitored for weight loss over 4 days. (D) Lung titer 2 0 determined 2-(n=5) and 4-days post infection (n=10). Dots on line graphs and bars on bar 2 1 graphs represent the group mean. ND indicates that no titers were detected. All error bars 2 2 represent SD. P-values were calculated using the two-tailed student's t-test, with: * P < 0.05, ** 2 3 P < 0.01, *** P < 0.001. 2 4 2 5 subtilis in a PBS solution was clarified, washed with the indicated solvents, and clarified again. Supernatants were decanted and retained, while the insoluble fractions were resuspended in PBS. The (A) insoluble fraction and (B) supernatants were then used to treat HCoV-229E and relative infectivity determined (n=3). (C, D, and E) Mass spectrometry performed was performed on PG (C) and ethanol wash (D). The peak corresponding to the molecular mass 1058 in the ethanol wash was then further fragmented (E) to determine the identity of the molecule. Representative spectra shown. For all dot plots, the centered bar represents the group mean and error bars the SD. For dot plots, each point represents the titer from an independent experiment while the group mean is indicated by a line. Each point on the line graph represents the group mean. All error bars represent SD. The two tailed students t-test was used to determine P-values: * P < 0.05, ** P < 0.01, *** P < 0.001. harvested and viral titer determined at day 2 and day 4. n=4 for all infected groups, n=2 for mock groups. (C and D) BALB/C mice were pretreated intranasally with 50 µl of either PBS (black) or surfactin in PBS (red). 18 hours later, BALB/C mice were infected with 10 4 PFU of SARS-CoV (MA15) and (C) monitored for weight loss over 4 days. (D) Lung titer determined 2-(n=5) and 4days post infection (n=10). Dots on line graphs and bars on bar graphs represent the group mean. ND indicates that no titers were detected. All error bars represent SD. P-values were calculated using the two-tailed student's t-test, with: * P < 0.05, ** P < 0.01, *** P < 0.001. and MERS-CoV (grey) were treated with PBS or the indicated cyclic lipopeptides in PBS and incubated for 2 hours at 37°C. Viral infectivity was then determined (n=3). (C) The indicated viruses were diluted PBS (black) or surfactin (red), incubated for 2 hours at 37°C, and viral infectivity determined (n=3). Viruses are abbreviated as follows: Coxsackievirus (CVB3), Dugbe (DUGV), Crimean-Congo hemorrhagic fever (CCHFV), Zika (ZIKV), Nipah (NiV), and Chikungunya (CHIKV), Una, Mayaro, Influenza A strains H1N1 and H3N2, and Ebola (EBOV). Bar graph bars represent the group means. Error bars represent SD. ND indicates that no titers were detected. The student's t-test was used to calculate p-values, with: * P < 0.05, ** P < 0.01, *** P < 0.001.
